162046-58-4

Basic information

• Product Name: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID
• Synonyms: TRANS-4-(TERT-BUTYLOXYCARBONYLAMINOMETHYL)-CYCLOHEXANOIC ACID;4-(TERT-BUTOXYCARBONYLAMINO-METHYL)-CYCLOHEXANECARBOXYLIC ACID;IFLAB-BB F2108-0060;BOC-AMC-OH;BOC-4-AMC-OH;BUTTPARK 52\04-68;TRANS-4-(T-BUTYLOXYCARBONYLAMINOMETHYL)-CYCLOHEXANOIC ACID;N-tert-Butoxycarbonyl-4-(aminomethyl)-cyclohexanecarboxylic acid
• CAS NO: 162046-58-4
• Molecular Formula: C₁₃H₂₃NO₄
• Molecular Weight: 257.33
• Product Categories: Amino Acids
• Mol File: 162046-58-4.mol

Chemical Properties

• Boiling Point: 410 °C at 760 mmHg
• Flash Point: 201.8 °C
• Appearance: /
• Density: 1.096 g/cm³
• Vapor Pressure: 7.17E-08mmHg at 25°C
• Refractive Index: 1.482
• Storage Temp.: Store at 0°C
• Solubility: Chloroform, Ethyl Acetate
• CAS DataBase Reference: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID(162046-58-4)
• EPA Substance Registry System: BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID(162046-58-4)

Safety Data

• Hazardous Substances Data: 162046-58-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID is used as an intermediate compound for the synthesis of cis-Tranexamic Acid (T714500), which is an antifibrinolytic agent. The application reason is that it blocks the lysine binding sites of plasminogen, thereby preventing excessive bleeding and promoting blood clotting.
Used in Hemostasis Applications:
In the medical field, BOC-(4-AMINOMETHYL)-CYCLOHEXANE-CARBOXYLIC ACID is used as a precursor for the development of hemostatic agents. The application reason is its role in the synthesis of cis-Tranexamic Acid, which helps in controlling bleeding and promoting blood clot formation, making it a valuable component in the treatment of various bleeding disorders and surgical procedures.

InChI:InChI=1/C13H23NO4/c1-13(2,3)18-12(17)14-8-9-4-6-10(7-5-9)11(15)16/h9-10H,4-8H2,1-3H3,(H,14,17)(H,15,16)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1197-18-8 trans-4-aminomethyl-cyclohexyl-carboxylic acid 
• 1197-17-7 4-aminomethyl-cyclohexanecarboxylic acid 
• 123-91-1 1,4-dioxane 

Downstream Products

• 877858-32-7 [4-(6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-cyclohexylmethyl]-carbamic acid tert-butyl ester 
• 100165-52-4 phthalidyl trans-4-aminomethylcyclohexanecarboxylate hydrochloride 
• 100165-49-9 1-(isopropyloxycarbonyloxy)ethyl trans-4-aminomethylcyclohexanecarboxylate hydrochloride 
• 100165-48-8 1-(ethyloxycarbonyloxy)ethyl trans-4-aminomethylcyclohexanecarboxylate hydrochloride 
• 16060-65-4 4-guanidinobenzoic acid 
• 1018674-46-8 trans-(4-Hydroxymethyl-cyclohexylmethyl)-carbamic acid tert-butyl ester 
• 180046-56-4 tert-butyl N-[[4-(cyanomethyl)cyclohexyl]methyl]carbamate 

Relevant articles and documents

XANTHINE DERIVATIVES AND USES THEREOF AS INHIBITORS OF BROMODOMAINS OF BET PROTEINS

The present invention relates to a compound having the following formula (I): (I) wherein: - R is a (C1-C6)alkyl group;- R'' is preferably H;- Ar is a (C5-C12)arylene radical;- X1 is -C(=O)- or -SO2-; and- R' is chosen from the group consisting of possibly substituted (C1-C6)alkyl, heteroaryl, (C5-C12)aryl, and (hetero)cycloalkyl groups, or a pharmaceutically acceptable salt and/or tautomeric form thereof, or its racemates, diastereomers or enantiomers.

Heterocyclic Compounds

This invention relates to heterocyclic compounds of the formulas shown in the specification. It also relates to methods for treating inflammatory diseases or immune diseases, developmental or degenerative diseases, and tissue injuries with one of the hete

ENZYME INHIBITORS

Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2is the side chain of a natural or non-natural alpha amino acid; Y is a bond, -C(=O)-, -S(=O)2-, -C(=O)O-, -C(O)NR3-, -C(=S)-NR3 , -C(=NH)NR3 or -S(=O)2NR3- wherein R3 is hydrogen or optionally substituted C1-C6 alkyl; L1 is a divalent radical of formula -(Alk1)m(Q)n(Alk2)p- wherein m, n and p are independently 0 or 1 , Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula -X2-Q1- or -Q1-X2- wherein X2 is -O-, S- or NRA- wherein RA is hydrogen or optionally substituted C1-C3 alkyl, and Q1 is an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5 - 13 ring members, AIk1 and AIk2 independently represent optionally substituted divalent C3-C7 cycloalkyl radicals, or optionally substituted straight or branched, C1-C6 alkylene, C2-C6 alkenylene ,or C2-C6 alkynylene radicals which may optionally contain or terminate in an ether (-O-), thioether (-S-) or amino (-NRA-) link wherein RA is hydrogen or optionally substituted C1-C3 alkyl; X1 represents a bond; -C(=O); or -S(=O)2-; -NR4C(=O)-, -C(=O)NR4-, -NR4C(=O)NR5- , -NR4S(=O)2-, or -S(=O)2NR4-wherein R4 and R5 are independently hydrogen or optionally substituted C1-C6 alkyl; z is 0 or 1 ; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R1R2NH-Y-L1-X1-[CH2]Z- and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.

VASOPRESSIN V1A ANTAGONISTS

The present invention concerns compounds inter alia according to general formula 1a. Compounds according to the invention are vasopressin V 1a receptor antagonists. Pharmaceutical compositions of the compounds are useful as treatment of dysmenorrhoea.

FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS

The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): (I) [INSERTCHEMICAL STRUCTURE HERE] (V)[INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these compounds, their use and processes for their preparation

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of oncoses, and their preparation. Exemplary compounds are: (a) 4-(5-indolylamino)-6-morpholinopyrimido[5,4-d]pyrimidine; (b) 4-(5-indolylamino)-6-[trans-(4-hydroxycyclohexyl)amino]pyrimido[5,4-d]pyrimidine; (c) 4-[(3-chloro-4-fluorophenyl)amino]-6-[4-(morpholinocarbonylmethyl)-1-piperazinyl]pyrimido[5,4-d]pyrimidine; (d) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-morpholinyl)amino]pyrimido[5,4-d]pyrimidine; (e) 4-[(3-chloro-4-fluorophenyl)amino]-6-(4-picolylamino)pyrimido[5,4-d]pyrimidine; (f) 4-[(3-chloro-4-fluorophenyl)amino]-6-[1-trifluoroacetyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine; (g) 4-[(3-chloro-4-fluorophenyl)amino]-6-(endo-tropinylamino)pyrimido[5,4-d]pyrimidine; and, (h) 4-[(3-chloro-4-fluorophenyl)amino]-6-(exo-tropinylamino)pyrimido[5,4-d]pyrimidine.

Pyrimido[5,4]-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof

Pyrimido[5,4-d]pyrimidines of the general formula [Figure] which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-[(3-Chloro-4-fluorophenyl)amino]-6-[1-methyl-4-piperidinylamino]pyrimido[5,4-d]pyrimidine, and 4-[(3-Chloro-4-fluorophenyl)amino]-6-[trans-4-dimethyl-aminocycohexylamino]pyrimido[5,4-d]pyrimidine.

Phenylalanine derivative and proteinase inhibitor

A phenylalanine derivative having the formula (I): STR1 wherein A represents STR2 B represents STR3 wherein m is 0, 1, or 2 and n is 3, 4, or 5; X represents (a) hydroxy, (b) nitro, (c) amino, (d) phenoxy which may be substituted with (i) halogen or (ii) nitro, (e) c1 -C4 alkyloxy which may be substituted wit (i) phenyl or (ii) benzoyl, (f) benzoyl, (g) pyridyloxy which may be substituted with (i) halogen or (ii) nitro, or (h) c1 -C4 alkyl which may by substituted with halogen; Y represents STR4 or --OR3 wherein R1 R2 are independently (a) hydrogen, (b) phenyl which may be substituted with (i) benzoyl, (ii) C1 -C4 alkylcarbonyl, (iii) C1 -C4 alkyl which may be further substituted with C1 -C4 alkoxycarbonyl or hydroxycarbonyl, (iv) C2 -C5 alkenyl which may be further substituted with hydroxycarbonyl or C1 -C4 alkoxycarbonyl, (v) C1 -C4 alkoxycarbonyl, or (vi) amidino, (c) pyridyl which may be substituted with halogen or carboxyl (d) imidazolyl, (e) pyrimidyl, (f) tetrazolyl, (g) thiazolyl which may be substituted with C1 -C4 alkyl which may be further substituted with C1 -C4 alkoxycarbonyl, (h) C1 -C6 alkyl which may be substituted with C1 -C4 alkoxy, C1 -C4 alkoxycarbonyl, phenyl, or benzoyl, (i) C5 -C7 cycloalkyl which may be substituted with C1 -C4 alkoxycarbonyl or (j) R1 and R2 may form, with the nitrogen atom attached thereto, (i) pyperazyl which may be substituted on the nitrogen atom with C1 -C4 alkyl which may be further substituted with phenyl, (ii) piperidino which may be substituted with carboxyl or C1 -C4 alkoxycarbonyl, (iii) pyrrolidyl which may be substituted with C1 -C4 alkoxycarbonyl, or (iv) morpholyl; and R3 represents (a) hydrogen, (b) C1 -C6 alkyl which may be substituted with (i) C1 -C4 alkoxy, (ii) pehnyl, or (iii) pyridyl, or (c) pyridyl; or a pharmaceutically acceptable acid salt thereof. This phenylalanine derivative is effective as a proteinase.

Phenylalanine derivative and proteinase inhibitor

A phenylalanine derivative having the formula (I): wherein mis 0, l, or 2 and nis 3, 4, or 5;, X represents (a) hydroxy, (b) nitro, (c) amino, (d) phenoxy which may be substituted with (i) halogen or (ii) nitro, (e) C1-C4 alkyloxy which may be substituted with (i) phenyl or (ii) benzoyl, (f) benzoyl, (g) pyridyloxy which may be substituted with (i) halogen or (ii) nitro, or (h) C1-C4 alkyl which may be substituted with halogen;, Y represents or -OR3 wherein, R1 and R2 are independently (a) hydrogen, (b) phenyl which may be substituted with (i) benzoyl, (ii) C1-C4 alkylcarbonyl, (iii) C1-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl or hydroxycarbonyl, (iv) C2-C5 alkenyl which may be further substituted with hydroxycarbonyl or C1-C4 alkoxycarbonyl, (v) C1-C4 alkoxycarbonyl, or (vi) amidino, (c) pyridyl which may be substituted with halogen or carboxyl (d) imidazolyl, (e) pyrimidyl, (f) tetrazolyl, (g) thiazolyl which may be substituted with C1-C4 alkyl which may be further substituted with C1-C4 alkoxycarbonyl, (h) C1-C6 alkyl which may be substituted with C1-C4 alkoxy, C1-C4 alkoxycarbonyl, phenyl, or benzoyl, (i) C5-C7 cycloalkyl which may be substituted with C1-C4 alkoxycarbonyl or (j) R1 and R2 may form, with the nitrogen atom attached thereto, (i) pyperazyl which may be substituted on the nitrogen atom with C1-C4 alkyl which may be further substituted with phenyl, (ii) piperidino which may be substituted with carboxyl or C1-C4 alkoxycarbonyl, (iii) pyrrolidyl which may be substituted with C1-C4 alkoxycarbonyl, or (iv) morpholyl; and, R3 represents (a) hydrogen, (b) C1-C6 alkyl which may be substituted with (i) C1-C4 alkoxy, (ii) phenyl, or (iii) pyridyl, or (c) pyridyl; or a pharmaceutically acceptable acid salt thereof. This phenylalanine derivative is effective as a proteinase.